Skip to content

EV / EBITDA at other companies

Eli Lilly logo
Eli LillyLLY
25.9×-24.4×
Theravance Biopharma logo
Theravance BiopharmaTBPH
199.8×
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
4.3×-1.7×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
171.7×
Innoviva, Inc. logo
Innoviva, Inc.INVA
7.5×+1.4×
Royalty Pharma logo
Royalty PharmaRPRX
13.9×+1.7×

Other financials

Income statement

See full
Revenue$22.5M+2.1%
Gross profit$21.3M+0.6%
Operating income-$9.4M-512%
Net income-$8.7M-422%
EPS (diluted)-$0.10

Balance sheet

See full
Cash & equivalents$37.5M+149%
Total debt$823.0K-48.1%
Total equity$101.3M+48.7%
Total assets$162.0M+24.8%

Cash flow

See full
Operating cash flow$3.2M+2,565%
CapEx$178.0K+45.9%
Free cash flow$3.0M+1,296%

Valuation

See full
Market cap$694.58M-4.7%
Enterprise value$657.9M-8.0%
P/S5.9×-1.3×

Profitability

See full
Gross margin95.1%-1.1pp
Operating margin-0.1%-10.4pp
Net margin6.3%+3.3pp
FCF margin2.6%

Returns & leverage

See full
Return on equity8.2%+4.2pp
Debt / equity0.0×
Current ratio4.6×+1.0×

Where this comes from

Calculated from Gyre Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s EV / EBITDA?
Gyre Therapeutics, Inc. (GYRE) reported EV / EBITDA of 242.1× in Q1 2026.
How has Gyre Therapeutics, Inc.'s EV / EBITDA changed year-over-year?
Gyre Therapeutics, Inc.'s EV / EBITDA increased by 310.9% year-over-year, from 58.9× to 242.1×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.